Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

1.7.7. Viale G;Regan MM;Dell’Orto P;Mastropasqua MG;MAIORANO, Eugenio;Rasmussen BB;MacGrogan G;Forbes JF;Paridaens RJ;Colleoni M;Làng I;Thurlimann;Mouridsen H;Mauriac L;Gelber RD;Price KN;Goldhirsch A;Gusterson BA;Coates AS

2011-01-01